[Form 4] ATAI Life Sciences N.V. Insider Trading Activity

Rhea-AI Filing Summary

ATAI Life Sciences N.V. reporting person Ryan Barrett (Chief Legal and Business Officer) was granted 175,000 stock options on 10/01/2025. The options have an exercise price of $5.20 and an expiration date of 10/01/2035. The award vests 25% after one year, with the remainder vesting in 36 substantially equal monthly installments thereafter. The Form 4 was signed on 10/03/2025.

Positive

• 175,000 stock options granted to reporting officer documented
• Clear vesting schedule: 25% after one year, then 36 monthly installments
• Exercise price and term specified: $5.20 strike, expires 10/01/2035

Negative

• None.

Insights

Corporate Governance Analyst

Insider option grant disclosed: 175,000 options at $5.20 on 10/01/2025.

The filing documents a grant of 175,000 stock options to the reporting officer with a $5.20 exercise price and a 10/01/2035 expiration. The vesting schedule is explicit: 25% vests after one year, then monthly vesting over the next 36 months.

This disclosure is material for understanding insider compensation and potential future share issuance; the filing is a routine Section 16 report required for officer transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrett Christopher Ryan Cave

(Last) (First) (Middle)

C/O ATAI LIFE SCIENCES N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183AT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$5.2	10/01/2025		A		175,000		(1)	10/01/2035	Common Shares	175,000	$0	175,000	D

Explanation of Responses:

1. The stock option shall vest as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Chief Legal and Business Officer

	/s/ Ryan Barrett	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did ATAI (ATAI) report on this Form 4?

The Form 4 reports a grant of 175,000 stock options to reporting person Ryan Barrett on 10/01/2025.

What are the key terms of the option grant disclosed for ATAI?

Options have an exercise price of $5.20, expire on 10/01/2035, and vest 25% after one year with the remainder vesting in 36 monthly installments.

Who is the reporting person and what is their role at ATAI?

The reporting person is Ryan Barrett, identified in the filing as Chief Legal and Business Officer.

When was the Form 4 signed and filed?

The signature on the form is dated 10/03/2025, and the earliest transaction date reported is 10/01/2025.

Does the Form 4 show any cash price paid for the underlying common shares?

The filing shows an exercise price of $5.20; the number of underlying common shares is 175,000.